Application of IVDr NMR spectroscopy to stratify Parkinson’s disease with absolute quantitation of blood serum metabolites and lipoproteins

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Georgy Berezhnoy - , University of Tübingen (Author)
  • Gyuntae Bae - , University of Tübingen (Author)
  • Leonie Wüst - , University of Tübingen (Author)
  • Claudia Schulte - , University of Tübingen, German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Claire Cannet - , Bruker Corporation (Author)
  • Isabel Wurster - , University of Tübingen, German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Milan Zimmermann - , University of Tübingen (Author)
  • Alexander Jäck - , German Center for Neurodegenerative Diseases (DZNE), Ludwig Maximilian University of Munich (Author)
  • Eike Jakob Spruth - , German Center for Neurodegenerative Diseases (DZNE), Charité – Universitätsmedizin Berlin (Author)
  • Julian Hellmann-Regen - , German Center for Neurodegenerative Diseases (DZNE), Charité – Universitätsmedizin Berlin (Author)
  • Sandra Roeske - , German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Dominik Pürner - , Technical University of Munich (Author)
  • Wenzel Glanz - , German Center for Neurodegenerative Diseases (DZNE), Otto von Guericke University Magdeburg (Author)
  • Fabian Maass - , University of Göttingen (Author)
  • Felix Hufschmidt - , German Center for Neurodegenerative Diseases (DZNE), University of Bonn (Author)
  • Ingo Kilimann - , German Center for Neurodegenerative Diseases (DZNE), University of Rostock (Author)
  • Elisabeth Dinter - , German Center for Neurodegenerative Diseases (DZNE), Department of Neurology, University Hospital Carl Gustav Carus Dresden (Author)
  • Okka Kimmich - , German Center for Neurodegenerative Diseases (DZNE), University of Bonn (Author)
  • Anna Gamez - , German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Johannes Levin - , German Center for Neurodegenerative Diseases (DZNE), Ludwig Maximilian University of Munich, Munich Cluster for Systems Neurology (SyNergy) (Author)
  • Josef Priller - , German Center for Neurodegenerative Diseases (DZNE), Charité – Universitätsmedizin Berlin, Technical University of Munich, University of Edinburgh (Author)
  • Oliver Peters - , German Center for Neurodegenerative Diseases (DZNE), Charité – Universitätsmedizin Berlin (Author)
  • Michael Wagner - , German Center for Neurodegenerative Diseases (DZNE), University of Bonn (Author)
  • Alexander Storch - , German Center for Neurodegenerative Diseases (DZNE), Rostock University Medical Centre (Author)
  • Paul Lingor - , German Center for Neurodegenerative Diseases (DZNE), Technical University of Munich, Munich Cluster for Systems Neurology (SyNergy) (Author)
  • Emrah Düzel - , German Center for Neurodegenerative Diseases (DZNE), Otto von Guericke University Magdeburg, University College London (Author)
  • Christoph van Riesen - , University of Göttingen, German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Ullrich Wüllner - , German Center for Neurodegenerative Diseases (DZNE), University of Bonn (Author)
  • Stefan Teipel - , German Center for Neurodegenerative Diseases (DZNE), University of Rostock (Author)
  • Björn Falkenburger - , Department of Neurology, German Center for Neurodegenerative Diseases (DZNE), University Hospital Carl Gustav Carus Dresden (Author)
  • Mathias Bähr - , University of Göttingen, German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Inga Zerr - , University of Göttingen, German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Gabor C. Petzold - , German Center for Neurodegenerative Diseases (DZNE), University of Bonn (Author)
  • Annika Spottke - , German Center for Neurodegenerative Diseases (DZNE), University of Bonn (Author)
  • Patricia Rizzu - , German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Frederic Brosseron - , German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Hartmut Schäfer - , Bruker Corporation (Author)
  • Thomas Gasser - , University of Tübingen, German Center for Neurodegenerative Diseases (DZNE) (Author)
  • Christoph Trautwein - , University of Tübingen (Author)

Abstract

The challenge of early detection and stratification in Parkinson’s disease (PD) is urgent due to the current emergence of mechanism-based disease-modifying treatments. In here, metabolomic and lipidomic parameters obtained by a standardized and targeted in vitro diagnostic research (IVDr) platform have a significant potential to address therapy-related questions and generate improved biomarker panels. Our study aimed to use IVDr nuclear magnetic resonance (NMR) spectroscopy to quantify metabolites and lipoproteins in PD blood serum from different cohorts to stratify metabolically driven subtypes of idiopathic and genetic PD. Serum aliquots from three neurodegeneration biobank cohorts (287 samples in total, including 62 PD patient samples with GBA mutation, 98/43 PD patient samples of early/late stages of disease duration, 20 PD samples from patients with mutations in recessive PD genes and some smaller subgroups of mitochondrial and double mutation cases) were prepared and analyzed with IVDr NMR spectroscopy, covering 39 blood serum metabolites and 112 lipoprotein parameters. Uni- and multivariate statistics were used to identify metabolism-driven changes under consideration of typical confounders such as age, sex and disease duration and set into context with clinical biomarkers such as CSF concentrations of alpha-synuclein, neurofilament light chain, and tau protein. Based on the different PD subgroups we performed a total of eight different comparisons. Highlights from these comparisons include increased citrate and dimethylglycine with a decrease of creatinine and methionine in healthy controls and early PD group compared to GBA, PD late and recessive PD. We furthermore identified decreased HDL-3 free cholesterol in genetic PD cases compared to sporadic subject samples (sum of the PD early and PD late groups). Considering medication, we found that the levodopa equivalent daily dose (LEDD) is mostly positively correlated with tyrosine and citrate in sporadic PD compared to pyruvate and phenylalanine in genetic PD. Cerebrospinal fluid levels of alpha-synuclein were negatively correlated with alanine. Further metabolites and lipoproteins with discriminatory power for double mutation PD cases involved ornithine, 2-aminobutyrate and 2-hydroxybutyrate as well as for mitochondrial phenotypes via LDL phospholipid, apolipoprotein and cholesterol subfractions. Quantitative IVDr NMR serum spectroscopy is able to stratify PD patient samples of different etiology and can contribute to a wider understanding of the underlying metabolism-driven alterations e.g. in energy, amino acid, and lipoprotein metabolism. Though our overall cohort was large, major confounders such as age, sex and medication have a strong impact. That is why absolute quantification and detailed patient knowledge about metabolic confounders, is a premise for future translation of NMR serum spectroscopy to routine PD diagnostics.

Details

Original languageEnglish
Article number17738
JournalScientific reports
Volume15
Issue number1
Publication statusPublished - Dec 2025
Peer-reviewedYes

External IDs

PubMed 40404791
ORCID /0000-0002-2387-526X/work/203813178

Keywords

ASJC Scopus subject areas

Keywords

  • Biomarkers, Blood, Dementia, GBA, Parkinson’s disease, Recessive inheritance